CCL Products Q1 Results FY26: Q1 PAT Rises 1.37% to ₹72.45 Crore; Revenue Up 36.51% YoY

CCL Products Q1 Results FY26: CCL Products posted its Q1 results on 5th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹72.45 crores against revenue of ₹1,055.64 crores. During Q1 FY26, the profit increase of the company was recorded at 1.37% YoY, and the revenue increase for the same period was 36.51%. 

CCL Products Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

CCL Products Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

CCL Products Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• CCL Products clocked Q1 FY26 consolidated revenue of ₹1,055.64 crores vs ₹773.29 crores. 
• On the profit front, CCL Products earned a consolidated PAT of ₹72.45crore in Q1 FY26. During FY25, the company’s PAT stood at ₹71.47 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 1.37% YoY, and revenue rose 36.51% YoY. 
• As per the standalone figures, the quarterly PAT of CCL Products has increased by 24.73% and revenue has increased by 23.91% YoY.

CCL Products Share Price Performance

On the opening bell of 6th August 2025, the shares of CCL Products opened at ₹855.00 per share. However, the initial gains are sustained as of now, and CCL Products shares are trading at ₹864.90 per share, higher than their opening price. 

Considering the long-term performance, CCL Products shares have yielded close to 36.52% returns in the past 1 year, and 5-year returns stand at 260.00%. Over the maximum timeframe, the CCL Products share provided 12,828.25% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in CCL Products shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Piramal Pharma Q1 Results FY26: Q1 Loss Narrows 7.83% to ₹81.70 Crore; Revenue Fails 0.89% YoY

Recent Articles

Best Penny Stocks for Long Term in India | Penny Stocks in 2025

Berger Paints Q1 Results FY26: Q1 PAT Narrows 11.01% to ₹314.63 Crore; Revenue Surged 3.55% YoY

Tega Industries Q1 Results FY26: Q1 PAT Falls 3.83% to ₹35.34 Crore; Revenue Jumps 4.74% YoY

Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY

BLS International Services Q1 Results FY26: Q1 PAT Soars 49.76% to ₹171.00 Crore; Revenue Up 44.23% YoY